Page 33 - Read Online

this marginal increase is not yet known, TACE-induced Liver Institute, Menoufiya University, Egypt.
hypoxia (and angiogenesis) might be a contributing factor
which needs further studies. The time point to measure Conflicts of interest
serum EGF (1 week after TACE) was chosen at random There are no conflicts of interest.
as an initial evaluation to also address the effect of TACE
on EGF, future studies focusing on including 2 additional REFERENCES
time points at 1 and 3 months are warranted. Philip et 1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
al. tested five EGFR inhibitors: Erlotinib, gefitinib, 2. Bruix J, Sherman M; Practice Guidelines Committee, American
[32]
cetuximab, lapatinib, and vandetanib. Erlotinib showed Association for the Study of Liver Diseases. Management of
activity in a phase II study with mixed HCC populations 3. hepatocellular carcinoma. Hepatology 2005;42:1208-36.
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer
with a median survival of 13 months, and it was being incidence in Egypt: results of the national population-based cancer
tested in combination with sorafenib in phase III. The registry program. J Cancer Epidemiol 2014;2014:437971.
other drugs either have not shown meaningful signals 4. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic
R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma:
of efficacy in phase II, such as gefitinib and lapatinib, genomic prognostic markers. Clin Cancer Res 2010;16:4688-94.
or are still in early stages of investigation. Gefinitib, a 5. Teofănescu I, Gologan E, Stefănescu G, Bălan G. Surveillance of
[33]
selective EGFR tyrosine kinase inhibitor, is reported to cirrhosis for hepatocellular carcinoma-clinical validation of new
successfully treat lung cancer. When investigating the serological biomarkers for improved diagnosis. Rev Med Chir Soc Med
Nat Iasi 2010;114:39-46. (article in Romanian)
effects of gefitinib on tumor-induced angiogenesis, it 6. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA,
was found that production of both VEGF and chemokine Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs
factor by EGF-stimulated HCC was more markedly CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in
advanced hepatocellular carcinoma. Cancer 2011;117:5094-102.
inhibited by gefitinib. Sogawa et al. in their study used 7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications
[34]
a novel human monoclonal antibody against EGFR as an of angiogenesis. Nature 2011;473:298-307.
imaging probe for HCC concluded that the radiolabeled 8. Zhang L, Wang JN, Tang JM, Kong X, Yang JY, Zheng F, Guo LY,
human anti-EGFR monoclonal antibody 048-006 has Huang YZ, Zhang L, Tian L, Cao SF, Tuo CH, Guo HL, Chen SY.
VEGF is essential for the growth and migration of human hepatocellular
the potential to be a safer imaging probe for predicting carcinoma cells. Mol Biol Rep 2012;39:5085-93.
tumor uptake of anti-EGFR antibody therapeutic agents 9. González L, Díaz ME, Miquet JG, Sotelo AI, Fernández D, Dominici
in HCC. Studying EGF and its receptors: pathway, FP, Bartke A, Turyn D. GH modulates hepatic epidermal growth factor
signaling in the mouse. J Endocrinol 2010;204:299-309.
therapies, and pipeline concluded that the exploitation 10. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq
of EGFR-directed therapies offered an improvement in H. Expression of epidermal growth factor receptors in human brain
tumors. Cancer Res 1984;44:753-60.
survival and quality of life in non-small cell lung cancer 11. Weichselbaum RR, Dunphy EJ, Beckett MA, Tybor AG, Moran WJ,
[35]
and colorectal carcinoma. Additional efforts should Goldman ME, Vokes EE, Panje WR. Epidermal growth factor receptor
be exerted directing further studies on EGFR-directed gene amplification and expression in head and neck cancer cell lines.
therapies to the poorly treated HCC patients. Head Neck 1989;11:437-42.
12. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal
growth factor-induced hepatocellular carcinoma: gene expression
In conclusion, serum EGF levels were found to be profiles in precursor lesions, early stage and solitary tumours.
significantly higher in HCC group in comparison with Oncogene 2005;24:1809-19.
cirrhosis, chronic hepatitis, and control groups. A serum 13. Lee JS, Thorgeirsson SS. Comparative and integrative functional
genomics of HCC. Oncogene 2006;25:3801-9.
level of EGF is a predictor factor of HCC progression and 14. Kannangai R, Sahin F, Torbenson MS. EGFR is phosphorylated at
together with older age were the only two predictive Ty845 in hepatocellular carcinoma. Mod Pathol 2006;19:1456-61.
factors for poor survival in patients with HCC after 1 15. Mroczkowski B, Reich M. Identification of biologically active
year of follow-up. There was an increase of serum epidermal growth factor precursor in human fluids and secretions.
Endocrinology 1993;132:417-25.
EGF levels in response to TACE without significant 16. Shaker MK, Abdella HM, Khalifa MO, El Dorry AK. Epidemiological
difference. Future studies should be conducted to characteristics of hepatocellular carcinoma in Egypt: a retrospective
analysis of 1313 cases. Liver Int 2013;33:1601-6.
focus on EGFR and their inhibitors as new promising 17. Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, Beltrami
therapeutic agents for HCC with the inclusion of CA, Bartoli E. Portal vein thrombosis in hepatocellular carcinoma:
more patients with respectable tumors amenable to age and sex distribution in an autopsy study. J Cancer Res Clin Oncol
1998;124:397-400.
resection, ablation, and/or liver transplantation who are 18. Abdel-Wahab M, El-Ghawalby N, Mostafa M, Sultan A, El-Sadany
expected to survive long enough to study any potential M, Fathy O, Salah T, Ezzat F. Epidemiology of hepatocellular
prognostic importance of EGF. carcinoma in lower Egypt, Mansoura Gastroenterology Center.
Hepatogastroenterology 2007;54:157-62.
Financial support and sponsorship 19. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma
This study was supported by the Hepatology and incidence, mortality, and survival trends in the United States from 1975
to 2005. J Clin Oncol 2009;27:1485-91.
Interventional Radiology Departments at the National 20. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic

24 Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016